Hypoglycemia is a condition characterized by abnormally low blood glucose levels, often affecting individuals with diabetes. It accounts for approximately 95.3% of those diagnosed with type 2 diabetes and 97.4% of individuals with type 1 diabetes globally. The hypoglycemia drug pipeline is expanding rapidly, driven by the demand for better therapies and the growing focus on patient-centric care. Recent advancements include novel glucose-responsive therapeutics and long-acting formulations. With increasing research investments and innovative drug candidates in development, the pipeline of hypoglycemia therapeutics is expected to experience significant growth in the coming years.
Major companies involved in the hypoglycemia pipeline drugs market include Vogenx, Inc., Amylyx Pharmaceuticals Inc., and others.
Leading drugs currently in the pipeline include Avexitide, Mizagliflozin, and others.
The growth of the hypoglycemia drug pipeline is driven by the rising prevalence of diabetes, increased demand for advanced glucose-regulating therapies, and ongoing innovations in long-acting and glucose-responsive formulations.
The Hypoglycemia Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into ypoglycemia therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for hypoglycemia. The hypoglycemia report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The hypoglycemia pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with hypoglycemia treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to hypoglycemia.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Hypoglycemia is a condition where blood glucose levels drop below normal, typically below 70 mg/dL. It occurs when there is an imbalance between glucose intake and insulin levels, often due to excessive insulin use, missed meals, or intense physical activity. Symptoms include dizziness, sweating, confusion, and in severe cases, unconsciousness if left untreated.
Hypoglycemia treatments focus on restoring blood glucose levels quickly. Mild cases are treated with fast-acting carbohydrates like glucose tablets or fruit juice. Severe cases may require intravenous glucose or glucagon injections. Long-term management involves adjusting medications, dietary planning, and continuous glucose monitoring to prevent recurring episodes.
Hypoglycemia is a significant concern for individuals with diabetes worldwide. A global study reported hypoglycemia in approximately 95.3% of type 2 diabetes (T2DM) cases and 97.4% of type 1 diabetes (T1DM) cases. In England, hypoglycemia requiring hospitalization is an increasing burden. In Japan, around 20,000 diabetes patients are hospitalized annually for hypoglycemia. In rural India, the prevalence of hypoglycemia is estimated at 57.44%, with 10% experiencing severe cases.
This section of the report covers the analysis of hypoglycemia drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total hypoglycemia clinical trials.
The drug molecule categories covered under the hypoglycemia pipeline analysis include small molecules, biologics, peptides, gene therapies, cell-based therapies, and others. The hypoglycemia report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for hypoglycemia.
The EMR report for the hypoglycemia drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed hypoglycemia therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in hypoglycemia clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for hypoglycemia. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of hypoglycemia drug candidates.
Avexitide, sponsored by Amylyx Pharmaceuticals Inc., is being evaluated in a Phase III study for post-bariatric hypoglycemia (PBH) related to Roux-en-Y gastric bypass. It targets GLP-1 receptors to reduce insulin secretion and stabilize blood glucose. The study aims to assess avexitide’s safety and efficacy in reducing hypoglycemic events compared to a placebo.
Mizagliflozin is an investigational oral, small-molecule drug candidate designed to lower postprandial glucose absorption and insulin secretion. It is a part of a Phase 2 crossover, placebo-controlled study, conducted by Vogenx, Inc., where it is being evaluated for its impact on adverse events and postprandial glucose excursions in post-bariatric hypoglycemia (PBH) patients. The study is anticipated to conclude by May 2025.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Hypoglycemia Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for hypoglycemia. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into hypoglycemia collaborations, regulatory environments, and potential growth opportunities.
Global Glucose Monitoring Devices Market Report and Forecast
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share